You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
智雲健康通過港交所上市聆訊 2022年一季度在疫情下收入5.5億,仍保持80%的高速增長
格隆匯 06-14 09:11
格隆匯6月14日丨據港交所文件顯示,6月13日,智雲健康通過港交所上市聆訊,摩根士丹利和摩根大通為聯席保薦人,其2021年收入17.57億元,增速109%。智雲健康通過為醫療價值鏈上的所有主要參與者(包括醫院、藥店、製藥公司、患者和醫生)提供解決方案,期望引領中國數字化慢病管理市場。根據弗若斯特沙利文報吿,基於截至2021年12月31日止的中國醫院和藥店SaaS部署量以及截至2021年通過智雲互聯網醫院開出的在線處方量,智雲健康已經成為了中國最大的數字化慢病管理解決方案提供商。智雲健康收入來自三個收入來源:院內解決方案、藥店解決方案、個人慢病管理解決方案及其他。2019-2021年,公司收入分別為5.24億元、8.39億元、17.57億元。2021年,智雲健康收入增長109%,毛利率進一步提升至32.4%,淨虧損率快速下降至(25)%。2022年一季度,智雲健康收入達到了5.5億元,收入增速同比高達約80%的同時,淨虧損率進一步下降到(15)%,財務狀況全面優化,有厚積薄發之勢。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account